Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020

--Campaign highlights Ardelyx commitment to advance the science of phosphate absorption to address significant unmet needs in the current treatment of hyperphosphatemia--

FREMONT, Calif., Oct. 22, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class medicines to improve the lives of patients with kidney and cardiovascular diseases, today announced the launch of its 'Can We Do Better?' Campaign at Kidney Week 2020, this year's virtual Annual Meeting of the American Society of Nephrology (ASN) that is now underway. With a new and deeper mechanistic understanding of phosphate absorption, Ardelyx is developing a new approach to advance patient care.

THE PROBLEM: Hyperphosphatemia has been shown to be an independent risk factor for high rates of cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) on dialysis. Unfortunately, most of these patients are unable to consistently achieve target phosphorus levels with the use of phosphate binders, the only currently available medications approved for the treatment of hyperphosphatemia:

• IN ANY GIVEN MONTH: ~42% of phosphate binder-treated patients on dialysis have phosphorus levels greater than the recommended target level of 5.5 mg/dL.*
• OVER A 6-MONTH PERIOD: ~77% of phosphate binder-treated patients on dialysis are unable to consistently maintain phosphorus levels